The use of targeted therapy in the management of epidermal growth factor receptor (EGFR)-
mutated non-small-cell lung cancer is an important milestone in the management of …

Background Patients with EGFR-mutant non-small-cell lung cancer generally have a
progression-free survival of 9–13 months while being treated with the EGFR tyrosine-kinase …

Introduction Non-small cell lung cancer (NSCLC) is a highly lethal disease. During the past
20 years, the epidermal growth factor receptor (EGFR) has been a relevant target for …

Systemic treatment of advanced non-small cell lung cancer (NSCLC) has undergone
remarkable changes in the last decade, with the introduction of targeted therapies and …

Purpose ARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus
gefitinib in treatment-naïve patients with advanced non–small-cell lung cancer (NSCLC) and …

Background Dacomitinib is an irreversible pan-EGFR family tyrosine kinase inhibitor.
Findings from a phase 2 study in non-small cell lung cancer showed favourable efficacy for …

Background Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor.
We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor …

Background ARCHER 1050, an ongoing, randomized, open-label, phase III trial of
dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung …

Aim: We evaluated reasons for dacomitinib dose reduction (DR) and examined adverse
event (AE) incidence, key efficacy end points (progression-free survival [PFS]/overall …

EGFR tyrosine-kinase inhibitors (TKIs) have now been firmly established as the first-line
treatment for non-small-cell lung cancer (NSCLC) patients harboring activating EGFR …